Vaccine plus immunotherapy for newly diagnosed HPV-positive throat cancer
Treatments studied
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests a new nasal vaccine combined with an immunotherapy drug (tislelizumab) given before surgery for people with HPV-positive oropharyngeal cancer. The goal is to help the immune system fight the cancer and potentially improve outcomes after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Newly diagnosed HPV-positive oropharyngeal squamous cell carcinoma (throat cancer) that has not spread to distant sites
- Cancer must be resectable (surgically removable) and you must be willing to have surgery
- Good overall health and organ function (blood counts, liver, kidney, and heart function within acceptable ranges)
- No prior immunotherapy, cancer vaccines, or certain other cancer treatments
- No active autoimmune disease, severe allergies to vaccine components, or serious heart, lung, or infectious disease conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of drugs and a vaccine before standard radiation for HPV-positive throat cancer. It aims to use a less intense radiation dose, which may reduce side effects while still being effective.
This study checks a blood test that looks for HPV tumor DNA to help doctors decide when to start routine treatment after surgery. It may help some people avoid starting treatment too early or too late based on how the test changes after the operation.
This trial tests if monitoring cancer DNA left in your blood after surgery can help decide if you need additional treatment. It is for people with HPV-positive oropharynx (throat) cancer who have a certain amount of cancer DNA detected before surgery.
This trial tests whether giving lower doses of radiation to certain parts of the throat can be just as effective as standard doses, while reducing side effects. It is for people with HPV-positive throat cancer, which tends to respond well to treatment.
This Phase 2 study tests a “risk-adapted” treatment plan for HPV-related throat cancer, using an HPV DNA blood test to help decide how treatment is done. If your baseline blood test shows detectable HPV DNA, the study may help tailor therapy to your risk and potentially improve outcomes while limiting unnecessary treatment.
This Phase 2 trial studies whether 5-azacytidine and nivolumab (alone and/or together) can work well and be tolerated in people with HPV-related throat cancer that can be surgically removed. The goal is to help shrink or control the cancer before resection and learn more from added tumor samples.
Hear when a new HPV Positive Oropharyngeal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.